Bristol Myers Squibb™

Investigational Trials of Idecabtagene Vicleucel (ide-cel; bb2121) in Patients With Multiple Myeloma

KarMMa-3

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)[1-3]

CURRENTLY ENROLLING GLOBALLY

NCT03651128 Phase 3

PRIMARY ENDPOINT
PFS

SELECT SECONDARY ENDPOINTS
OS, EFS, ORR, MRD, CR rate, DOR, TTR, AEs, and pharmacokinetics

KEY ELIGIBILITY CRITERIA

- R/R multiple myeloma with 2–4 prior lines of treatment
- Refractory to the last anti-myeloma treatment regimen prior to study entry (documented PD during treatment or within 60 days of completion)
- Previous treatment with daratumumab, a proteasome inhibitor, and an immunomodulatory compound–containing regimen for ≥2 consecutive cycles
- Previously achieved a response to at least 1 prior treatment
- ECOG PS ≤1

TREATMENT

R 2:1

- **Arm A: bb2121 (n=~254)**
  150–450 x 10^6 CAR+ T cells, following leukapheresis, bridging therapy (optional), and lymphodepletion
  → **PFS follow-up period until PD**
- **Arm B: standard regimens, investigator's choice (n=~127)**
  - *DPd, or*
  - *DVd, or*
  - *IRd, or*
  - *EPd, or*
  - *Kd*

  → **Option for those who discontinue due to PD: bb2121**
  150–450 x 10^6 CAR+ T cells, following leukapheresis, bridging therapy (optional), and lymphodepletion

FOLLOW-UP

Follow up for safety and survival

Long-term follow-up protocol
(up to 15 years after last bb2121 infusion)

CONTACT: ClinicalTrialDisclosure@bms.com

KarMMa-2

ALSO ENROLLING

NCT03601078 Phase 2

A Phase 2, Multicohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma[6]

CONTACT: ClinicalTrialDisclosure@bms.com

KarMMa™-4

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High-Risk, Newly Diagnosed Multiple Myeloma[3-5]

CURRENTLY ENROLLING ACROSS THE US

NCT04196491 Phase 1

PRIMARY ENDPOINTS
Dose-limiting toxicity rates and AEs

SELECT SECONDARY ENDPOINTS
CR rate, ORR, DOR, time to CR, time to start maintenance, feasibility of initiating maintenance, PFS, OS, and pharmacokinetics

KEY ELIGIBILITY CRITERIA

- Newly diagnosed, high-risk (R-ISS stage III and cytogenetic abnormalities or serum LDH >ULN), symptomatic multiple myeloma
- Measurable disease at initial diagnosis
- ECOG PS ≤1
- Previously treated with ≤3 cycles of induction anti-myeloma therapy (C1, C2, C3)

TREATMENT *Estimated N=60*

- **Induction therapy Cycles 1–3**
  - ***C1:*** *RVd, KRd, CyBorD, D-RVd, or D-KRd*
  - ***C2:*** *RVd or KRd*
  - ***C3:*** *RV or KR*
- → **Leukapheresis**
- → **Stem cell harvest***
- → **Induction therapy Cycle 4**
  RVd or KRd
- → **Lymphodepletion: fludarabine + cyclophosphamide**
- → **bb2121**
  150–800 x 10^6 CAR+ T cells
- → **Maintenance therapy**
  Lenalidomide

FOLLOW-UP

Follow up for efficacy and safety

Long-term follow-up protocol
(up to 15 years after last bb2121 infusion)

***Stem cell harvest is recommended either after Cycle 3 following leukapheresis or after Cycle 4 but prior to chemotherapy.**

CONTACT: ClinicalTrialDisclosure@bms.com

Idecabtagene vicleucel (ide-cel; bb2121) in collaboration with bluebird bio™.

The safety and efficacy of idecabtagene vicleucel (ide-cel; bb2121) and/or its uses are under investigation and have not been established.
There is no guarantee that idecabtagene vicleucel (ide-cel; bb2121) will receive health authority approval or become commercially available in any country for the uses being investigated.

AE, adverse event; **ANC**, absolute neutrophil count; **CR**, complete response; **CyBorD**, cyclophosphamide, bortezomib, dexamethasone; **D-KRd**, daratumumab, KRd; **DOR**, duration of response; **DPd**, daratumumab, pomalidomide, dexamethasone; **DVd**, daratumumab, bortezomib, dexamethasone; **D-RVd**, daratumumab, RVd; **ECOG PS**, Eastern Cooperative Oncology Group Performance Status; **EFS**, event-free survival; **EPd**, elotuzumab, pomalidomide, dexamethasone; **IMWG**, International Myeloma Working Group; **IRd**, ixazomib, lenalidomide, dexamethasone; **Kd**, carfilzomib, dexamethasone; **KR**, carfilzomib, lenalidomide; **KRd**, KR, dexamethasone; **LDH**, lactate dehydrogenase; **MM**, multiple myeloma; **MR**, minimal response; **MRD**, minimal residual disease; **ORR**, overall response rate; **OS**, overall survival; **PD**, progressive disease; **PFS**, progression-free survival; **R-ISS**, Revised Multiple Myeloma International Staging System; **R/R**, relapsed and refractory; **RV**, lenalidomide, bortezomib; **RVd**, RV, dexamethasone; **TCR**, time to complete response; **TTR**, time to response; **ULN**, upper limit of normal.

1. Clinicaltrials.gov. NCT03651128. Accessed April 28, 2021. **2.** Dalforge M, et al. KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, vs standard regimens in relapsed and refractory multiple myeloma. Poster at ASH 2020. Abstract 2323. **3.** Clinicaltrials.gov NCT03435796. Accessed April 28, 2021. **4.** Clinicaltrials.gov NCT04196491. Accessed April 27, 2021. **5.** Usmani S, et al. KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in high-risk newly diagnosed multiple myeloma. Poster at ASH 2020. Abstract 1418. **6.** Clinicaltrials.gov. NCT03601078. Accessed April 27, 2021.